Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1997-10-29
2000-03-14
Kemmerer, Elizabeth
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 12, 4353201, 435 697, 435325, 4352523, 530350, 536 234, A61K 3816, C12N 510, C12N 1562, C12N 1563
Patent
active
060373210
DESCRIPTION:
BRIEF SUMMARY
This invention relates to vasoactive intestinal peptide ("VIP") and cross-reactive peptides. In particular, this invention relates to peptides capable of inducing antibodies which neutralize the activity of VIP. This invention also relates to tandemly repeated peptides derived from VIP or from cross-reactive peptides, which can elicit a broad immune response. The present invention is useful for increasing egg production in bird species and for increasing efficiency of feed utilization and rate of gain in food producing animals.
BACKGROUND OF THE INVENTION
VIP has been proven to be a potent releaser of avian prolactin ("PRL") in vivo and in vitro. Prolactin is a hormone produced by the anterior pituitary and it is well established that prolactin can initiate incubation behaviour in birds such as turkeys, bantam hens and many species of wild birds.
Incubation behaviour leads to early cessation of egg laying and has a fundamental role in avian reproduction. The incubation behaviour has been of great interest to scientists and producers of hatching eggs and of particular interest in the field of turkey breeding since reproductive efficiency of turkey hens is low in comparison with chickens. This low efficiency has been associated with incubation behaviour and there is convincing evidence that increased PRL secretion causes reduction in circulating gonadotropins, ovarian regression, and the shift from the egg laying to the incubation phase of the reproductive cycle in the turkey.
Incubation behaviour may be suppressed by blocking the biological effect of VIP on prolactin induction. Passive immunization of incubating chickens with anti-VIP serum has been found to induce a reduction in plasma PRL and pituitary PRL mRNA, resulting in termination of incubation behaviour. Active immunization of female turkeys with chicken VIP has also been reported to suppress circulating PRL and inhibit the expression of incubation behaviour resulting in a substantial increase in egg production. Therefore, active and passive immunization against VIP may be useful for modifying the egg-laying performance of avian species. Among the desired effects are that hens lay eggs for a longer period of time, that there is an increase in the number of eggs laid, and that non-laying hens commence laying eggs.
Further, VIP was initially identified for its vasoactive properties in mammals. VIP causes relaxation of isolated gastric and intestinal smooth muscle cells. VIP-induced relaxation is mediated by high-affinity VIP receptors and can be inhibited by VIP antiserum and selective VIP antagonists.
Critical affected segments of the gastrointestinal tract occur at the pyloric-duodenal junction, the junction between the small intestine and the large intestine, and the anal sphincter. Immunization of food-producing animals against VIP may result in increased tone of these segments leading to increased efficacy of absorption of food with a consequent increased rate of feed efficiency and rate of weight gain.
Immunization against VIP presently entails chemically synthesizing the full length of VIP and conjugating the resulting peptide to a carrier molecule. Commercial application of this non-recombinant technique is expensive and difficult, and moreover conjugation of the VIP with a carrier molecule is highly unpredictable, therefore resulting in low yields of useful antigenic proteins. Further, this technique would require, firstly, a ready source of VIP antigens and, further, antigens which can elicit a broad immune response. These immunogens are not currently available. Thus, it is desirable to develop a recombinant system whereby antigenic fusion proteins are made and the conjugation step is avoided.
SUMMARY OF THE INVENTION
Accordingly, the present invention relates to a nucleotide sequence comprising (1) a DNA sequence coding for at least one copy of vasoactive intestinal peptide, and/or at least one copy of a cross-reactive protein, and/or at least one copy of a peptide fragment derived from vasoactive intestinal peptide and/or a cross-re
REFERENCES:
patent: 5165924 (1992-11-01), Shewen et al.
patent: 5238823 (1993-08-01), Potter et al.
patent: 5273889 (1993-12-01), Potter et al.
patent: 5336491 (1994-08-01), Berget et al.
patent: 5476657 (1995-12-01), Potter
patent: 5506120 (1996-04-01), Yamamoto et al.
patent: 5557033 (1996-09-01), Halawani
patent: 5723129 (1998-03-01), Potter et al.
Bowie et al., "Deciphering the Message in Protein Sequences Tolerance to Amino Acid Substitutions," Science 247:1306-1310(1990).
Donelly et al., "Immunization with Polynucleotides: A Novel Approach to Vaccination," The Immunologist 2(1):20-26 (1994).
Ngo et al., "Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox," The Protein Folding Problem and Tertiary Structure Prediction pp. 492-495 (1994).
Sharp et al., "The Role of Hypothalamic Vasoactive Intestinal Polypeptide in the Maintenance of Prolactin Secretion in Incubating Bantam Hens: Observations Using Passive Immunization, Radioimmunoassay and Immunohistochemistry," J. Endocrinology 122(1):5-13 (1989).
Wells, "Additivity of Mutational Effects in Proteins," Biochemistry 29(37):8509-8517 (1990).
Youngren et al., "Active Immunization with Vasoactive Intestinal Peptide Prevents the Secretion of Prolactin Induced by Electrical Stimulation of the Turkey Hypothalamus," General and Comparative Endocrinology 95:330-336(1994).
"DNA Cloning" vols. I and II (D.N. Glover ed.) 1985.
"Handbook of Experimental Immunology", vols. 1-10 (D.W. Weir and C.C. Blackwell eds.) Blackwell Scientific Pub., (1980).
"Isolation of a Neuropeptide Corresponding to the N-Terminal 27 Residues of the Pituitary Adenylate Cyclase Activating Polypeptide with 38 Residues (PACAP38)", Biochem. And Biophysical Research Comm. 2:643-648(1990).
Abe et al., Endocrinology 116:1383-1390(1985).
Arnadout et al., Endocrinology 119:2052-2057(1986).
Bacon et al., Poultry Science 62:2400-2473(1983).
Christophe, Biochimica et Biophysica Acta 183-199(1993).
Donnelly et al., The Immunologist 2/1:20-26(1994).
El Halawani et al., Poultry Science Suppl. 74(6):157 Abstract #467 (1995).
El Halawani et al., Biology of Reproduction 52:179-183(1995).
El Halawani et al., Poultry Science 72:906-911(1993).
El Halawani et al., General and Comparative Endocrinology 80:138-145(1990).
El Halawani et al., General and Comparative Endocrinology 87:436-442(1992).
El Halawani et al., General and Comparative Endocrinology 78:66-73(1990).
El Halawani et al., Poultry Science 62:48(1989).
El Halawani et al., Poultry Science 70:38(1991).
El Halawani et al., Poultry Science 68:48-49(1989).
Grider et al., Annals NY Acad. Science 527:369-377(1988).
Hall et al., General and Comparative Endocrinology 62:171-184(1986).
Haller et al., Poultry Science 40:155-163(1961).
Johnson, Poultry Science 62:2474-2478(1983).
Lea et al., Hormones and Behavior 25:283-294(1991).
Macnamee et al., General and Comparative Endocrinology 62:470-478(1990).
Maniatis et al., Molecular Cloning: A Laboratory Manual (1982).
March et al., Journal of Reproduction and Fatality 101: 227-233(1994).
Mauro et al., Endocrinology 125:1795-1804(1989).
Mauro et al., Poultry Science 70:79(1991).
Michalkiewicz et al., Am. J. Physiol. (Endocrino. Metab. 29) 266:E905-913(1994).
Nagy et al., Endocrinology 122:364-366(1988).
Nestor et al., Poultry Science 65:1405-1409(1986).
Nestor et al., Poultry Science 65:1410-1412(1986).
Opel et al., Proceedings of the Society for Experimental Biology and Medicine 187:455-460 (1988).
Pitts et al., Poultry Science 71: Abstract #61 (1992).
Pitts et al., Poultry Science 59: Abstract #177 (1993).
Proudman et al., Poultry Science 69:1209-1214(1990).
Proudman J.A., Poultry Science (Suppl. 156)74: Abstract #468(1995).
Proudman et al., Proceedings of the Society for Experimental Biology and Medicine 187:448-454(1988).
Robinson et al., Poultry Science 72:912-922(1993).
Rozenboim et al., Poultry Science 72:94 abstract #282(1993).
Rozenboim et al., Biology of Reproduction 48:1129-1134(1993).
Rozeboim et al., Biology of Reproducti
Cox Graham J.M.
Manns Jack
Weeks-Levy Carolyn
Biostar Inc.
Kemmerer Elizabeth
LandOfFree
Fusion proteins comprising vasoactive intestinal peptide or PACA does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Fusion proteins comprising vasoactive intestinal peptide or PACA, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Fusion proteins comprising vasoactive intestinal peptide or PACA will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-169168